A study published in the Journal of Clinical Endocrinology and Metabolism  explores the relationship between weight loss, vitamin D status, | Cardiology ...

Dec. 3, 2024 — Using significantly higher doses of vitamin D than recommended for five years did not affect the incidence of type 2 diabetes in elderly men and women, according to a new ...

Low concentrations of 25-OH vitamin D causes secondary hyperparathyroidism (high levels of parathyroid hormone or PTH). This means a person loses more calcium from his/her bones when PTH is ...

the "normal" blood level of vitamin D (25-OH vitamin D) was based on the amount needed to keep PTH from becoming abnormally high. Again, PTH at high levels can cause calcium loss from the bone ...

Vitamin D (calciferol) and vitamin K2 (menaquinone) are essential nutrients supporting several aspects of health. Vitamin D is beneficial for bone and heart health and inflammation. Vitamin K2 is ...

Dec. 3, 2024 — Using significantly higher doses of vitamin D than recommended for five years did not affect the incidence of type 2 diabetes in elderly men and women, according to a new ...

Over the last few days, I have seen two patients who had serious complications because of a vitamin D overdose, which is toxic for the human body. It was a reminder how we treat supplements callously ...

Millions of postmenopausal women find themselves facing a diagnosis of osteoporosis, but what does that mean for their daily ...

FRAX is a tool to evaluate fracture risk based on individual patient models, incorporating clinical risk factors and bone ...

Taylor Leamey writes about all things wellness, specializing in mental health, sleep and nutrition coverage. She has invested hundreds of hours into studying and researching sleep and holds a ...

Taylor Leamey writes about all things wellness, specializing in mental health, sleep and nutrition coverage. She has invested hundreds of hours into studying and researching sleep and holds a ...

Orsini has been selected by Ascendis Pharma as a specialty pharmacy partner for YORVIPATH® (palopegteriparatide), an FDA-approved parathyroid hormone analog (PTH(1-34)) indicated for the treatment of ...